STOPCAP M1
Menu
  • Home
  • What is STOPCAP M1?
    • Systematic reviews
      • The FAME approach
      • Docetaxel
      • Zoledronic acid
      • Abiraterone
      • Prostate RT
      • Network
    • Surrogate outcomes
      • ICECAP M0
    • Repository of patient data
  • Who is running STOPCAP M1?
    • Programme Management Group
    • International Advisory Group
    • Key Collaborators
    • Collaborative Group
  • Patient & Public Involvement
    • PPI and STOPCAP M1
    • Recent STOPCAP M1 results
    • Prostate Cancer Resources
  • News
  • Sitemap

Protocols, SAPS, Appendices

ADT versus ADT + Docetaxel
  • Protocol v2.0 (13August 2021)
  • Statistical analysis plan v2.0 (16July2021)
ADT versus ADT + ARSI (with or without docetaxel)
  • Protocol v4.0 (01February2024)
  • Statistical analysis plan v3.0 (06February2024)
Network meta-analysis of systemic treatments (ADT, Docetaxel, ARSI)
  • Protocol v1.0 (01February2024)
  • Statistical analysis plan v3.0 (07February2024)
Protocol appendices
  • STOPCAP M1 Charter v2.1 (06Feb2024)
  • STOPCAP M1 Data transfer guide v5.0 (Sept2022)
  1. Home
  2. Protocol

STOPCAP M1

MRC Clinical Trials Unit at UCL
90 High Holborn
2nd Floor
London
WC1V 6LJ

Email. mrcctu.stopcapm1@ucl.ac.uk

Twitter. https://twitter.com/MRCCTU

Quick links

  • Publications
  • Protocol
Funded by PCUK

Prostate Cancer UK is a registered charity in England and Wales (1005541) and in Scotland (SC039332). Registered company 02653887.
  • © 2025
  • Sitemap
  • Cookies
  • RSS
  • Page last updated: 09-Feb-2024 14:28